Marc, Casandra; Achille, Allahnah; Fregeau, Genevieve; Hannou, Lydia; Vachon, Isabelle; Vaillancourt, Cathy 
ORCID: https://orcid.org/0000-0003-0543-6244; Lavoie, Julie L et Bertagnolli, Mariane
(2022).
Pro-angiogenic Effects Of The Thrombospondin-1 Inhibitor Lskl In Preeclampsia Models
In: 29th Scientific Meeting of the International Society of Hypertension (Hypertension Kyoto 2022), October 12 - 16, 2022, Kyoto, Japan.
Résumé
Introduction: Preeclampsia (PE) is characterized by high blood pressure, proteinuria and/or multi-organ damage, reaching 10% of all pregnancies globally. To date, no medication can treat PE. We recently identified an upregulation of the antiangiogenic protein Thrombospondin-1 (THBS1) in human and experimental PE. THBS1 is a main activator of latent TGF-β. We postulate that THBS1-mediated TGF-β activation can contribute to impair placental angiogenesis during PE. In this study, we aim to test the effects of LSKL, an inhibitor of TGF-β activation by THBS1, on angiogenesis in placentas of a mouse model of PE and in human placental endothelial cells exposed to PE-like conditions.
Methods: Heterozygous female mice overexpressing human angiotensinogen and renin (PE) or C57BL/6 (control) were treated with LSKL or control peptide SLLK (280 μM, sc) at gestational day (GD) 14.5 (n=3 pregnant mouse/group). Placentas (n=4-9/pregnancy) were collected at GD 18.5. Placental expressions of TGF-β1, β2, total/phospho SMAD2 were assessed by western blot and angiogenesis by immunohistochemistry. Endothelial cells were extracted by magnetic sorting from human placentas (n=4) of healthy pregnancies. Cells were treated with LSKL or SLLK (30 μM) under hypoxia (0.5% vs. 8% O2) or thrombin (10 u/mL). THBS1 expression in cells was assessed by immunofluorescence. Cell angiogenesis was quantified by the number of closed tubes formed on matrigel (per 15,000 cells, 4h).
Results: LSKL treatment reduced the expression of TGF-β2 (P<0.01) and phospho-SMAD2 (P<0.05) and significantly improved angiogenesis (P<0.05) in placentas of PE mouse versus control. In cells, both thrombin (P<0.05) and hypoxia (P<0.05) significantly increased THBS1 expression. Thrombin (P<0.01) and hypoxia (P<0.05) significantly impaired cell angiogenesis on matrigel (P<0.01), which was prevented by LSKL treatment (P<0.01). LSKL similarly reduced TGB-β2 (p<0.05) and phospho-SMAD2 (P<0.05) expressions in endothelial cells under thrombin and hypoxia cell exposure.
Conclusion: Our results describe a significant pro-angiogenic effect of LSKL treatment by regulating THBS1 and TGF-β2 mechanisms in an experimental model of PE and in human placental endothelial cells exposed to PE-like conditions.
| Type de document: | Document issu d'une conférence ou d'un atelier |
|---|---|
| Informations complémentaires: | Présentation orale A004 Hypertension 79 (Suppl. 1) https://www.ahajournals.org/doi/10.1161/hyp.79.suppl_1.004 |
| Mots-clés libres: | - |
| Centre: | Centre INRS-Institut Armand Frappier |
| Date de dépôt: | 04 janv. 2024 07:50 |
| Dernière modification: | 04 janv. 2024 07:50 |
| URI: | https://espace.inrs.ca/id/eprint/13421 |
Gestion Actions (Identification requise)
 |
Modifier la notice |